Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
Journal Title
Blood Advances
Publication Type
epub ahead of print
The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-based therapies for patients with AML, a pertinent question is whether treatment can be safely ceased among patients who have achieved sustained remission. We hypothesized that a proportion of patients opting to cease therapy may benefit from a treatment-free remission (TFR) period without indefinite treatment. We report the retrospective outcomes of 29 patients in remission for a minimum of 12 months on VEN-based therapy, with 55% continuing therapy (CONT) until disease progression and the 45% electively ceasing treatment (STOP). With follow up exceeding 5 years, we observed a median TFR lasting 45.8 months among the STOP cohort, with >50% of patients still in sustained remission at the data cut-off. The risk of relapse and duration of relapse-free and overall survival were similar between the two cohorts. Factors favoring sustained TFR within the cohort included NPM1 and/or IDH2 mutation at diagnosis, complete remission without measurable residual disease, and at least 12 months of VEN-based combination therapy prior to treatment cessation.
WEHI Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
Open Access at Publisher's Site
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2022-05-11 10:40:07
Last Modified: 2022-05-11 11:09:02
An error has occurred. This application may no longer respond until reloaded. Reload 🗙